Histopathology of Giant-cell Tumor of Bone – Current Concept
Vol 3 | Issue 2 | Sep-Dec 2017 | Page 2-5| Sanjeev Shah.
Authors: Sanjeev Shah [1].
[1] Department of Pathology, Unipath Laboratory Specialty Ltd, Beside JMC House, Ahmedabad, Gujarat, India.
Address of Correspondence
Dr. Sanjeev Shah,
102, First floor, Sanoma Plaza, Opp. Parimal Garden, Beside JMC House, Ellisbridge, Ahmedabad – 380006, Gujarat, India.
E-mail: dcp72002@yahoo.com
Abstract
GCTB is a primary osteolytic bone tumor which can recurrence, undergo metastasis, and malignant transformation. Current understanding of molecular pathogenesis of GCTB particularly RANK on osteoclast-like GCs and RANKL on stromal cells and development of newer agents such as denosumab and INF-α has tremendously impacted management of patients with GCTB.
Keywords: Giant-cell tumor of bone histopathology, current concept.
References
1. Turcotte RE. Giant cell tumor of bone. OrthopClin North Am 2006;37:35-51.
2. Georgi PG, Svetoslav S, Iva ND, Boycho L. Giant cell tumor of bone: Current review of morphological, clinical, radiological, and therapeutic characteristics. J Clin Exp Investig 2014;5:475-85.
3. Nielsen GP, Andrew ER, Vikram D, Francis JH, Susan VK, Daniel IR. Diagnostic Pathology Bone: Amirsys; 2013. p. 371-95.
4. Fletcher CD, Bridge JA, Hogendoorn P, Mertens F. WHO Classification of Tumours of Soft Tissue and Bone. 4th ed. Lyon: France IARC Press; 2013. p. 321-4.
5. Dominkus M, Ruggieri P, Bertoni F, Briccoli A, Picci P, Rocca M, et al. Histologically verified lung metastases in benign giant cell tumours–14 cases from a single institution. Int Orthop 2006;30:499-504.
6. Kay RM, Eckardt JJ, Seeger LL, Mirra JM, Hak DJ. Pulmonary metastasis of benign giant cell tumor of bone. Six histologically confirmed cases, including one of spontaneous regression. Clin Orthop Relat Res 1994;302:219-30.
7. Gamberi G, Benassi MS, Böhling T, Ragazzini P, Molendini L, Sollazzo MR, et al. Prognostic relevance of C-myc gene expression in giant-cell tumor of bone. J Orthop Res 1998;16:1-7.
8. Schoedel KE, Greco MA, Stetler-Stevenson WG, Ohori NP, Goswami S, Present D, et al. Expression of metalloproteinases and tissue inhibitors of metalloproteinases in giant cell tumor of bone: An immunohistochemical study with clinical correlation. Hum Pathol 1996;27:1144-8.
9. Hoch B, Inwards C, Sundaram M, Rosenberg AE. Multicentric giant cell tumor of bone. Clinicopathologic analysis of thirty cases. J Bone Joint Surg Am 2006;88:1998-2008.
10. Dhillon MS, Prasad P. Multicentric giant cell tumour of bone. ActaOrthopBelg 2007;73:289-99.
11. Bertoni F, Bacchini P, Staals EL. Malignancy in giant cell tumor of bone. Cancer 2003;97:2520-9.
12. Nascimento AG, Huvos AG, Marcove RC. Primary malignant giant cell tumor of bone: A study of eight cases and review of the literature. Cancer 1979;44:1393-402.
13. Anract P, De Pinieux G, Cottias P, Pouillart P, Forest M, Tomeno B, et al. Malignant giant-cell tumours of bone. Clinico-pathological types and prognosis: A review of 29 cases. Int Orthop 1998;22:19-26.
14. Dickson BC, Li SQ, Wunder JS, Ferguson PC, Eslami B, Werier JA, et al. Giant cell tumor of bone express p63. Mod Pathol 2008;21:369-75.
15. Behjati S, Tarpey PS, Presneau N, Scheipl S, Pillay N, Van Loo P, et al. Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone. Nat Genet 2013;45:1479-82.
16. Akpalo H, Lange C, Zustin J. Discovered on gastrointestinal stromal tumour 1 (DOG1): A useful immunohistochemical marker for diagnosing chondroblastoma. Histopathology 2012;60:1099-106.
17. Cleven AG, Briaire-de Bruijn I, Szuhai K, Bovee JV. DOG1 expression in giant-cell-containing bone tumours. Histopathology 2016;68:938-45.
18. Althof PA, Ohmori K, Zhou M, Bailey JM, Bridge RS, Nelson M, et al. Cytogenetic and molecular cytogenetic findings in 43 aneurysmal bone cysts: Aberrations of 17p mapped to 17p13.2 by fluorescence in situhybridization. Mod Pathol 2004;17:518-25.
19. Oliveira AM, Perez-Atayde AR, Dal Cin P, Gebhardt MC, Chen CJ, Neff JR, et al. Aneurysmal bone cyst variant translocations upregulate USP6 transcription by promoter swapping with the ZNF9, COL1A1, TRAP150, and OMD genes. Oncogene 2005;24:3419-26.
20. Kim Y, Nizami S, Goto H, Lee FY. Modern interpretation of giant cell tumor of bone: Predominantly osteoclastogenic stromal tumor. Clin Orthop Surg 2012;4:107-16.
21. López-Pousa A, Martín Broto J, Garrido T, Vázquez J. Giant cell tumour of bone: New treatments in development. Clin Transl Oncol 2015;17:419-30.
22. Xu SF, Adams B, Yu XC, Xu M. Denosumab and giant cell tumour of bone-a review and future management considerations. Curr Oncol 2013;20:e442-7.
23. Branstetter DG, Nelson SD, Manivel JC, Blay JY, Chawla S, Thomas DM, et al. Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone. Clin Cancer Res 2012;18:4415-24.
24. Heymann D. Anti-RANKL therapy for bone tumours: Basic, pre-clinical and clinical evidences. J Bone Oncol 2012;1:2-11.
25. Roux S, Amazit L, Meduri G, Guiochon-Mantel A, Milgrom E, Mariette X, et al. RANK (receptor activator of nuclear factor kappa B) and RANK ligand are expressed in giant cell tumors of bone. Am J ClinPathol 2002;117:210-6.
| How to Cite this article: Shah S. Histopathology of Giant-cell Tumor of Bone – Current Concept. Journal of Bone and Soft Tissue Tumors Sep-Dec 2017;3(2): 2-5. |
